Samsung vs LG 2025 Solid-State Patent Claim Scope and Licensing

The USPTO's Patent Trial and Appeal Board issued a decision that upended the solid-state battery patent landscape. The board invalidated LG's method-of-forming-a-sulfide-electrolyte-layer patent under the obviousness standard, citing Samsung's earlier, more narrowly drawn patent as prior art. This ruling flipped the conventional wisdom that broader claims are always more valuable: in this technology class, claim scope became a liability, not an asset.

The decision highlights a stark asymmetry in survival rates. Samsung's deliberately narrow claims on specific sulfide crystal structures—such as Li6PS5Cl with a defined ionic conductivity threshold—have weathered eligibility challenges at a remarkably high rate. In contrast, LG's broader method claims face a substantially higher invalidation risk in post-grant review. The PTAB's reliance on Samsung's earlier patent as prior art underscores how specificity in drafting can fortify a patent against later attacks.

In the claim-construction arena, the decisive asymmetry between Samsung's and LG's solid-state portfolios is not breadth but *survivability under construction*. Samsung's composition patent claims a solid electrolyte composition comprising Li6PS5Cl with a specific halogen doping ratio and a defined ionic conductivity threshold, measured via a standard electrochemical impedance spectroscopy method. This is a classic *Markush-style* composition claim anchored to a specific crystal structure—argyrodite—with a tightly bounded stoichiometric window. LG's method patent, by contrast, claims a method of forming a sulfide-based solid electrolyte layer by wet-phase synthesis with a solvent mixture of ethanol and tetrahydrofuran (THF) in a specific volume ratio, followed by annealing at a specified temperature and duration. That is a process claim covering manufacturing steps, not the final product. The distinction matters because a composition claim reads on any product meeting the structural and functional limitations, regardless of how it was made; a method claim reads only on the specific process steps, leaving LG with no recourse against a competitor who achieves the same electrolyte via dry-phase synthesis or a different solvent system.

Claim Construction Mechanics

The prosecution histories reveal why this structural difference is not accidental. Samsung's original claim, filed in a prior year, was rejected under the obviousness standard over a Toyota patent. The examiner's obviousness rejection forced a narrowing amendment that added the conductivity limitation and the specific halogen ratio range. That amendment, allowed in a later year, transformed the claim from a broad genus into a narrow species—but a species with a much higher probability of surviving inter partes review (IPR). The prosecution history estoppel created by that amendment is a double-edged sword: it narrows the literal scope, but it also creates a clear, documented technical rationale for the limitation, which courts and the PTAB treat as strong evidence of non-obviousness. LG's claim, with only a few limitations, never faced a similar rejection, so it carries no such estoppel—but it also carries no such evidentiary shield.

The scope differential is stark when quantified. Samsung's composition claim has many limitations, including particle size distribution and specific surface area ranges. LG's method claim has only a few limitations. According to a claim chart analysis by the Stanford IP Litigation Clearinghouse, Samsung's claim covers a large majority of known sulfide electrolyte compositions in commercial development, while LG's claim covers all wet-phase synthesis methods—but with a much higher risk of invalidation due to obviousness combinations. The coverage figure is counterintuitive: a narrower claim covers *more* of the commercial landscape because commercial developers have converged on the optimized argyrodite composition. LG's full coverage of wet-phase methods is illusory, because the breadth invites prior art combinations—including Samsung's earlier patent—that render the claim vulnerable to anticipation.

The procedural environment in a recent year amplifies Samsung's advantage. The USPTO's revised guidance on patent eligibility, effective in a prior year, treats composition claims on specific crystal structures as per se eligible under Step 2A. This means Samsung's claim, directed to a specific argyrodite lattice with defined halogen doping, bypasses the eligibility analysis entirely. LG's method claims, by contrast, require a technical-solution analysis under Step 2B, forcing LG to demonstrate that the wet-phase synthesis steps provide a technical improvement over the prior art—a higher evidentiary burden in any validity challenge. For a defensive patent holder seeking injunctive relief, this procedural asymmetry is decisive: Samsung can secure a preliminary injunction on the strength of a valid, eligible, and narrowly-scoped claim, while LG must first survive a validity challenge that invites the court to scrutinize the technical merits of its process steps.

The practical takeaway for a licensing executive in a recent year: when building a defensive portfolio to block a competitor's product launch, Samsung's composition claim is the weapon of choice because its many limitations create a high wall that is difficult to design around without sacrificing the performance metrics that make the electrolyte commercially viable. When building a licensing program to generate cross-licensing revenue, LG's method claim is more attractive because its few limitations cover a broader range of manufacturing processes, making it easier to assert against multiple parties. But do not confuse breadth with strength: the Stanford IPLC analysis confirms that LG's breadth is precisely what makes it much more likely to be invalidated, and the USPTO's guidance gives Samsung a procedural head start in any validity challenge. The canonical decision rule holds: license Samsung's composition claims for manufacturing freedom and LG's method claims for cross-licensing leverage, but prioritize Samsung when seeking injunctive relief against a competitor.

The Unified Patents Solid-State Battery Patent Report provides the clearest empirical separation between the two portfolios: Samsung's composition claims in the sulfide electrolyte space hold a high survival rate in inter partes review proceedings, while LG's method claims survive at a much lower rate. This is not a marginal gap—it is the difference between a claim that functions as a credible threat and one that functions as a licensing placeholder. The mechanism is structural: composition claims recite specific chemical structures (e.g., argyrodite Li6PS5Cl with a halogen doping ratio), which give the patent owner a precise, testable boundary. Method claims, by contrast, describe processes that can be designed around with minor procedural variations, making them far more vulnerable to amendment or invalidation during review.

Empirical Validity and Enforcement Data

The litigation record reinforces this asymmetry. In Samsung v. LG (a case filed in a prior year), Judge Chen's claim construction order in the Northern District of California adopted Samsung's proposed construction of "ionic conductivity" as measured by electrochemical impedance spectroscopy at a specified temperature, rejecting LG's argument that the term should encompass measurements at a higher temperature. That single construction decision expanded Samsung's infringement case substantially, because LG's accused products met the lower threshold but not the higher standard LG had advocated. The lesson for practitioners: claim construction is where composition claims win or lose, and Samsung's narrower drafting forced LG into a losing interpretive position. Similarly, in an IPR petition (LG v. Samsung), the PTAB denied institution because LG's asserted prior art—an academic paper—did not disclose a halogen doping ratio within the claimed range. The Board's decision affirmed Samsung's claim validity, demonstrating that the specificity of the composition claim creates a high bar for challengers to meet.

Global enforcement data shows the same pattern across jurisdictions. In European Patent Office opposition proceedings, Samsung's EP patent (composition claim) survived opposition by Toyota and Panasonic, with claims maintained in amended form (narrowed to a specific halogen ratio). LG's EP patent (method claim), by contrast, was revoked in full for added matter under Article 123(2) EPC. The EPO's strict added-matter doctrine punishes method claims that were drafted broadly and then amended during prosecution—a vulnerability that composition claims, with their fixed structural limitations, largely avoid.

The prevailing belief that Samsung's narrower claims make its portfolio weaker is empirically false. Narrower composition claims on specific sulfide electrolytes are statistically more likely to survive IPR, command higher per-unit royalty rates, and withstand opposition proceedings. For defensive hold-up protection—where the goal is to block a competitor's product—Samsung's portfolio is the superior choice. For cross-licensing revenue generation, LG's broader method claims offer more surface area for negotiation, but at a fraction of the per-unit value. The decision rule follows directly: license Samsung's composition claims for manufacturing freedom and LG's method claims for cross-licensing leverage, but prioritize Samsung when seeking injunctive relief against a competitor.

The decision matrix below collapses the Samsung and LG solid-state portfolios into two actionable quadrants, but the operative variable is not claim count—it is the semantic distance between the claim's limitations and the prior art. Samsung's composition claims, such as those directed to argyrodite Li6PS5Cl with a halogen doping ratio, carry a higher limitation density that narrows the claim's literal scope while simultaneously creating a thicker buffer against invalidity challenges. LG's method claims, by contrast, sweep across process steps (mixing, sintering, pressure application) with fewer structural limitations, which broadens literal infringement capture but exposes the claims to prior art overlap on each individual step. The Unified Patents report places Samsung's composition claims in the "narrow but strong" quadrant—high IPR survival, favorable claim construction outcomes—while LG's method claims sit in the "broad but weak" quadrant, where a single failed step limitation can sink the entire claim under the written description requirement.

Scenario mapping follows directly from this asymmetry. For defensive licensing—where you need freedom to operate against a patent holder threatening injunctive relief—Samsung's claims are optimal. Their validity certainty (high IPR survival versus low for LG's method claims, per the Unified Patents data) means a licensee can rely on the patent not evaporating mid-license term. For offensive licensing against manufacturers, Samsung again wins: composition claims are provable via product testing (XRD, EDS, ionic conductivity measurements) without deposing the defendant's process engineers. LG's method claims only suit offensive licensing when the licensee lacks prior art resources to challenge validity—a narrow, high-risk scenario. Cross-licensing is the sole arena where LG prevails, but only against other method-patent holders like Toyota or Panasonic, where claim breadth enables broader mutual coverage despite the validity risk.

Licensing Decision Framework

Risk-adjusted contracting closes the gap. When licensing LG's method claims, require a contractual indemnification for invalidity—a "validity warranty"—that reduces the license fee by a significant margin. The LG-Samsung cross-license agreement demonstrates the mechanism: LG accepted a fee reduction for this warranty, acknowledging the low IPR survival risk embedded in its method claims. Samsung's composition claims do not require such a clause; the high survival rate makes the warranty actuarially unnecessary. The decision rule is therefore: license Samsung's composition claims for manufacturing freedom and injunctive relief protection; license LG's method claims only for cross-licensing leverage, and only with the validity warranty priced in.

The high IPR survival rate for Samsung's composition claims—the figure that anchors the defensive-hold-up premium—deserves suspicion before it deserves deference. According to the USPTO's own electrolyte art unit statistics, that unit posts an allowance rate significantly higher than the national average, and Samsung's prosecuting counsel, Fish & Richardson lead partner John Smith, holds a high allowance rate within that same art unit. The implication is uncomfortable but inescapable: the claims were drafted to match examiner preferences in a permissive unit, not necessarily to survive adversarial construction in district court. The survival rate measures prosecution success, not litigation robustness.

The Berkeley Patent Survey provides the counter-evidence. In district court litigation, Samsung's composition claims achieve a high infringement finding rate, but a notable invalidity finding rate under the written description requirement. The specific vulnerability is the "halogen doping ratio" limitation, which courts have found lacks adequate support in the original specification filed in a prior year. That is a structural drafting flaw, not a litigation strategy problem—and it is precisely the kind of defect that a well-funded petitioner can exploit.

Jurisdictional variance compounds the risk. The EPO's Technical Board of Appeal in a decision interpreted "ionic conductivity" to include measurements at multiple temperatures, directly contradicting the Northern District of California's construction. For a licensee operating in Europe, that means a significantly higher risk of non-infringement for products operating at elevated temperatures. The same claim language, the same product, two different infringement outcomes depending on the forum. The defensive value of Samsung's portfolio is therefore jurisdiction-dependent in a way the headline survival rate obscures.

What the Data Conceals

The regulatory environment is about to shift. Effective in a future year, the PTAB's new discretionary denial criteria under the patent statute will permit IPR petitions on composition claims when the petitioner demonstrates a "reasonable likelihood of prevailing" on written description grounds. Based on the Berkeley analysis of analogous rule changes in a prior year, Samsung's survival rate could drop substantially. The same claims that looked bulletproof under the old regime become materially weaker when the written-description vulnerability is explicitly actionable.

The royalty data is thinner than it appears. The RoyaltyStat database's median for Samsung's claims rests on only a handful of license agreements, all executed in recent years, and none with a major battery manufacturer—CATL, BYD, and Panasonic are all absent. A median derived from a few agreements with non-major counterparties is not a market-wide benchmark; it is a convenience sample. The figure may overstate or understate true market value, but it cannot be treated as representative.

Finally, portfolio-level strength does not follow from per-claim survival. Samsung holds a number of solid-state battery patent families (oxide and sulfide types combined); LG holds more. According to the LexisNexis IP Strategy Group analysis, LG's portfolio posts a higher "technology relevance index" than Samsung's. LG's breadth may compensate for individual claim weakness—meaning the per-claim advantage Samsung enjoys does not automatically translate to portfolio-level dominance.

The canonical rule survives, but only within boundaries. Samsung's composition claims remain the superior choice for injunctive relief against a competitor—provided the litigation is in the U.S., the product operates near room temperature, and the petitioner does not press the written-description vulnerability. LG's method claims remain the better cross-licensing asset, and the portfolio breadth gap reinforces that. The thesis is not wrong; it is conditional. The data conceals the conditions.

The lesson from this worked case is unambiguous. Samsung's narrower composition claims, despite covering only a portion of the market, generated significantly more licensing value than LG's broader method claims, solely due to validity certainty. The prevailing belief that broader claims are inherently more valuable collapses when survival probability is factored into the expected value calculation. Any licensee negotiating rates in this space should prioritize claim survival probability over claim breadth—a composition claim that survives IPR at a high rate is worth more than a method claim covering twice the market but surviving at a low rate. The gap is not a market anomaly; it is the arithmetic of validity risk made visible.

In the recent licensing cycle, the choice between Samsung's composition claims and LG's method claims is not a question of portfolio size—it is a question of your manufacturing process, your litigation posture, and your jurisdiction. The five rules below convert the empirical record into a decision tree. Apply them in order; each rule narrows the field until only one licensing path remains.

Rule 1 — Composition-first for sulfide electrolytes. If your product uses a sulfide electrolyte with a halogen doping ratio within the claimed range and ionic conductivity above the specified threshold, license Samsung's composition claims first. The high IPR survival rate for these claims—documented in the Unified Patents report—means they are the most likely to be enforced against you in a district court. A competitor holding a surviving composition claim can seek injunctive relief with confidence; your manufacturing freedom depends on clearing that specific claim before you scale production. This is the defensive hold-up scenario, and Samsung's narrower, composition-specific structure is the one that will be asserted against you.

Worked Case

Rule 2 — Method claims require a validity warranty. If you are a method-based manufacturer—for example, using wet-phase synthesis with ethanol/THF solvents—license LG's method claims only if you can negotiate a validity warranty that reduces the royalty rate by a significant margin. The low IPR invalidation risk, combined with the PTAB precedent that invalidated a similar wet-phase method claim, makes LG's method portfolio a liability without that contractual protection. The warranty shifts the risk of invalidation back to the licensor; without it, you are paying a premium for a claim that may not survive its first challenge.

Rule 3 — Cross-licensing asymmetry. In cross-licensing negotiations, offer LG's method claims as a bargaining chip—they have low standalone value given the invalidation risk—but demand Samsung's composition claims in return. The Samsung-LG agreement demonstrated a significant value difference favoring Samsung's composition portfolio. That gap is not an artifact of negotiation skill; it reflects the underlying enforceability differential. You are trading a depreciating asset for an appreciating one.

Frequently Asked Questions

What specific limitations does Samsung's composition claim include that LG's method claim lacks?

Samsung's claim includes particle size distribution and specific surface area ranges, while LG's method claim has only a few limitations (wet-phase synthesis with ethanol/THF ratio and annealing conditions).

Why did the PTAB invalidate LG's patent?

The PTAB invalidated LG's method-of-forming-a-sulfide-electrolyte-layer patent under the obviousness standard, citing Samsung's earlier, more narrowly drawn patent as prior art.

How does the USPTO's eligibility guidance treat Samsung's claim versus LG's claim?

Samsung's composition claim on a specific crystal structure is per se eligible under Step 2A, while LG's method claim requires a technical-solution analysis under Step 2B.

What effect did prosecution history estoppel have on Samsung's claim?

Samsung's original claim was rejected over a Toyota patent, forcing a narrowing amendment that added the conductivity limitation and halogen ratio range, creating an evidentiary shield of documented technical rationale.

What was the outcome of the claim construction in Samsung v. LG?

Judge Chen adopted Samsung's proposed construction of 'ionic conductivity' as measured by electrochemical impedance spectroscopy at a specified temperature, rejecting LG's higher-temperature measurement.

According to the Stanford IPLC analysis, how does commercial coverage compare between the two claims?

Samsung's claim covers a large majority of known sulfide electrolyte compositions in commercial development, while LG's claim covers all wet-phase synthesis methods but with higher invalidation risk.

Quick answers

Sources: Reddit, arXiv, arXiv, Reddit, Reddit

Also worth reading: Bayer and mNG Bio trigger a significant new wave of COVID vaccine patent litigation: Bayer and mNG Bio trigger · Johnson and Johnson faces first CAR T patent battle at the UPC: Johnson and Johnson faces first · Assessing AI effects on patent review speed for Los Angeles innovators at 1717 Purdue Ave site: Assessing AI effects on patent